Minimal residual disease assessment in chronic lymphocytic leukaemia

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 3, 2007, Pages 499-512

  Sayala, Hazem A ^a   Rawstron, Andy C ^a   Hillmen, Peter ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

chronic lymphocytic leukaemia; minimal residual disease

Indexed keywords

ALEMTUZUMAB; CD19 ANTIGEN; CD6 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLUDARABINE; MITOXANTRONE; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CRITERION VARIABLE; CYTOTOXICITY; DRUG EFFICACY; DRUG MEGADOSE; ERADICATION THERAPY; FLOW CYTOMETRY; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MOLECULAR CLONING; MONOTHERAPY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY ANALYSIS; STANDARDIZATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ALLELES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIGENS, CD5; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION; VIDARABINE;

EID: 34547911055     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2007.03.004     Document Type: Review

References (56)

1. San Miguel J.F., Vidriales M.B., Lopez-Berges C., et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 98 6 (2001 September 15) 1746-1751
2. Buccisano F., Maurillo L., Gattei V., et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20 10 (2006 October) 1783-1789
3. Biondi A., Valsecchi M.G., Seriu T., et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 14 11 (2000 November) 1939-1943
4. van Dongen J.J., Seriu T., Panzer-Grumayer E.R., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 352 9142 (1998 November 28) 1731-1738
5. Raff T., Gokbuget N., Luschen S., et al. Molecular relapse in adult standard risk ALL patients detected by prospective MRD-monitoring during and after maintenance treatment - data from the GMALL 06/99 and 07/03 trials. Blood 109 3 (2007 Feb 1) 910-915
6. Goldman J. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Current Opinion in Hematology 12 1 (2005 January) 33-39
7. Sarasquete M.E., Garcia-Sanz R., Gonzalez D., et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 90 10 (2005 October) 1365-1372
8. Cheson B.D., Bennett J.M., Rai K.R., et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Report of the NCI-sponsored Working Group. American Journal of Hematology 29 3 (1988) 152-163
9. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 12 (1996 June 15) 4990-4997
10. Rawstron A.C., Kennedy B., Evans P.A., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98 1 (2001 July 1) 29-35
11. Voena C., Ladetto M., Astolfi M., et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 11 10 (1997 October) 1793-1798
12. Arnold A., Cossman J., Bakhshi A., et al. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. The New England Journal of Medicine 309 26 (1983 December 29) 1593-1599
13. Owen R.G., Johnson R.J., Rawstron A.C., et al. Assessment of IgH PCR strategies in multiple myeloma. Journal of Clinical Pathology 49 8 (1996 August) 672-675
14. van Dongen J.J., Langerak A.W., Bruggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17 12 (2003 December) 2257-2317
15. Provan D., Bartlett-Pandite L., Zwicky C., et al. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after marrow transplantation. Blood 88 6 (1996 September 15) 2228-2235
16. Bottcher S., Ritgen M., Pott C., et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 18 10 (2004 October) 1637-1645
17. Liang R., Chan V., Chan T.K., et al. Detection of immunoglobulin gene rearrangement in lymphoid malignancies of B-cell lineage by seminested polymerase chain reaction gene amplification. American Journal of Hematology 43 1 (1993 May) 24-28
18. Aubin J., Davi F., Nguyen-Salomon F., et al. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia 9 3 (1995 March) 471-479
19. Pfitzner T., Engert A., Wittor H., et al. A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia. Leukemia 14 4 (2000 April) 754-766
20. van der Velden V., Hochhaus A., Cazzaniga G., et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17 6 (2003 June) 1013-1034
21. Bruggemann M., Droese J., Bolz I., et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 14 8 (2000 August) 1419-1425
22. Moreno C., Villamor N., Colomer D., et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 107 11 (2006 June 1) 4563-4569
23. Vuillier F., Claisse J.F., Vandenvelde C., et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leukemia & Lymphoma 7 3 (1992 June) 195-204
24. Lenormand B., Bizet M., Fruchart C., et al. Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. Leukemia 8 6 (1994 June) 1019-1026
25. Cabezudo E., Matutes E., Ramrattan M., et al. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia 11 11 (1997 November) 1909-1914
26. Robertson L.E., Huh Y.O., Butler J.J., et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 80 1 (1992 July 1) 29-36
27. Hillmen P. Beyond detectable minimal residual disease in chronic lymphocytic leukemia. Seminars in Oncology 33 2 supplement 5 (2006 April) S23-S28
28. Rawstron A, Villamor N, Zehnder J, et al. International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL. ASH Annual Meeting Abstracts Abstract 15(104) 2004.
29. Rawstron A.C., de Tute R., Jack A.S., and Hillmen P. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukemia-specific assay for use in rituximab-containing regimens. Leukemia 20 (2006) 2102-2110
30. Rawstron AC, Villamore N, Ritgen M, et al. International Standardized Approach for Flow Cytometric Residual Disease Monitoring in Chronic Lymphocytic Leukemia. Leukemia 2007 May; 21(5):956-964.
31. Keating M.J., O'Brien S., Lerner S., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92 4 (1998 August 15) 1165-1171
32. O'Brien S.M., Kantarjian H.M., Cortes J., et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology 19 5 (2001 March 1) 1414-1420
33. Bosch F., Ferrer A., Lopez-Guillermo A., et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. British Journal of Haematology 119 4 (2002 December) 976-984
34. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 23 18 (2005 June 20) 4079-4088
35. Wierda W., O'Brien S., Wen S., et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 23 18 (2005 June 20) 4070-4078
36. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology 23 13 (2005 May 1) 2971-2979
37. Esteve J., Villamor N., Colomer D., et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 15 3 (2001 March) 445-451
38. Esteve J., Villamor N., Colomer D., et al. Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood 99 5 (2002 March 1) 1873-1874
39. Mattsson J., Uzunel M., Remberger M., et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. Leukemia 14 2 (2000 February) 247-254
40. Milligan D.W., Fernandes S., Dasgupta R., et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood 105 1 (2005 January 1) 397-404
41. Wendtner C.M., Ritgen M., Schweighofer C.D., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18 6 (2004 June) 1093-1101
42. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. The New England Journal of Medicine 343 24 (2000 December 14) 1750-1757
43. Bosch F, Ferrer A, Villamor N et al. Combination Chemotherapy with Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Induces a High Response Rate in Previously Untreated CLL. ASH Annual Meeting Abstracts 106[Abstract 718] 2005.
44. Huhn D., von Schilling C., Wilhelm M., et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98 5 (2001 September 1) 1326-1331
45. Itala M., Geisler C.H., Kimby E., et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukemia: results from a Nordic multicentre study. European Journal of Haematology 69 3 (2002 September) 129-134
46. Byrd J.C., Murphy T., Howard R.S., et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. Journal of Clinical Oncology 19 8 (2001 April 15) 2153-2164
47. O'Brien S.M., Kantarjian H., Thomas D.A., et al. Rituximab dose escalation study in chronic lymphocytic leukemia. Journal of Clinical Oncology 19 5 (2001 April 15) 2165-2170
48. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 10 (2002 May 15) 3554-3561
49. Montillo M., Tedeschi A., Miqueleiz S., et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 24 15 (2006 May 20) 2337-2342
50. O'Brien S.M., Kantarjian H.M., Thomas D.A., et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98 12 (2003 December 15) 2657-2663
51. Pavletic Z.S., Bierman P.J., Vose J.M., et al. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Annals of Oncology 9 9 (1998 September) 1023-1026
52. Ritgen M., Stilgenbauer S., von Neuhoff N., et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104 8 (2004 October 15) 2600-2602
53. Meloni G., Proia A., Mauro F., et al. Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring. Haematologica 85 9 (2000 September) 952-960
54. Schetelig J., Thiede C., Bornhauser M., et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. Journal of Clinical Oncology 21 14 (2003 July 15) 2747-2753
55. Rai KR, Byrd JC, Peterson B, et al. A Phase2 Trial of Fludarabine followed by Alemtuzumab (Campath 1H) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients with Active Disease: cancer and Leukemia Group B (CALGB) Study 19901. Blood 100(11) 205a-Abstract number 772. 16-11-2002.
56. Rai KR, Byrd J, Peterson B, et al. Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia(CLL) :CAL GB study 19901. Blood 102(11) 676a-Abstract number 2506. 2003.